Abologix Company

ABOLOGIX is developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein. The treatment is designed for patients that do not respond to traditional cancer therapies.

Investors

Industry: PharmTech
Headquarters: Geneva

Visit Website
Register and Claim Ownership